Impact of race/ethnicity, donor and recipient age, and donor on survival after allogeneic transplant in the post-transplant cyclophosphamide era
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for hematologic malignancies, and outcomes have improved over time [ 1 ]. However, Hispanic and non-Hispanic Black (NHB) patients have worse overall survival (OS) compared to non-Hispanic White (NHW) patients and are less likely to utilize an unrelated HCT donor [ 2 , 3 ], but this difference has not been evaluated in the post-transplant cyclophosphamide (PTCy) era. PTCy reduces GvHD and allows for increased availability of alternative allogeneic donors in minority patients [ 4 ].
Authors
- Theresa Hahn (ORCID: https://orcid.org/0000-0002-3835-8855)
- Shernan G. Holtan (ORCID: https://orcid.org/0000-0002-5054-9419)
- Nandita Khera (ORCID: https://orcid.org/0000-0002-0577-3155)
- Nisha M. Nair (ORCID: https://orcid.org/0009-0008-8567-3314)
- Megan M. Herr (ORCID: https://orcid.org/0000-0001-5768-9396)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Mayo Clinic Hospital (US)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1038/s41408-026-01670-0
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases